Latest in Research & Development

Quotient Sciences and CPI to accelerate RNA drug development with joint venture

The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence

Find out more

Ensuring drug safety using AI models for adverse drug reaction prediction

Adverse drug reactions (ADRs) are a significant cause of hospital admissions and treatment discontinuation worldwide
See more

Naobios, Nuvonis and the European Vaccine Initiative collaborate to manufacture influenza challenge agent

Working with the Inno4Vac consortium, Naobios will leverage Nuvonis’s Vero Cell Bank to support the development of a controlled human infection model based on the influenza virus A(H3N2)

Wegovy cuts risk of heart attack, stroke or death by 57% compared with tirzepatide

Study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments
You need to be a subscriber to read this article.
Click here to find out more.

Formulation meets function: addressing palatability in drug development (part I)

Patient adherence to treatment regimens is inextricably linked to the palatability of medications, with consequences that can be far more serious than simply leaving a bad taste in one’s mouth

Hamilton Health Sciences chosen for BirchBioMed burn scar treatment trial

BirchBioMed announces Hamilton Health Sciences’ (HHS) Centre for Burn Research in Ontario as the first contracted clinical trial site for its Phase II/III randomised study of the naturally based compound: FS2.

Indena and TCG GreenChem join forces to advance next-generation ADC technologies

Indena and TCG GreenChem are pleased to announce a new strategic collaboration aimed at accelerating the development of innovative and market-ready payload-linkers: the key component of antibody-drug conjugates (ADCs)

Lilly's Verzenio (abemaciclib) increases overall survival in HR+/HER2- high-risk early breast cancer with 2 years of therapy

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared with endocrine therapy alone

Bowel cancer test could be used to detect other serious diseases, study finds

A new study, led by experts at the University of Nottingham, has found that people who test positive following a stool test for symptoms of bowel cancer had double the risk of death after one year than people who had negative tests ... and most of the deaths were because of other causes

Sustainability that performs: how GEA is building a better future for pharma

By embedding ESG principles into pharmaceutical manufacturing, GEA is delivering measurable sustainability performance without compromising compliance or productivity

Latest posts in Research & Development

Debiopharm pushes the boundaries of innovation in antibiotic development against gonorrhoea

First participant dosed with Debiopharm’s Debio 1453, a new drug candidate to address the high unmet need of multidrug-resistant infections with Neisseria gonorrhoeae

Charles River joins EASYGEN Consortium to advance bedside CAR-T cell therapy manufacturing

The Consortium aims to develop a fully automated, hospital-based platform that's capable of manufacturing personalised cell therapies in 24 hours

Hongene to supply exNA oligonucleotide technology under new licensing deal

Hongene Biotech Corporation announces a non-exclusive licensing agreement with the UMass Chan Medical School to produce and supply extended nucleic acid (exNA) monomers and exNA-modified oligonucleotides for research use

Phase I clinical trial with AKIR001 progresses to next step following completion of first cohort

Akiram Therapeutics announces the completion of the first cohort in the clinical Phase I trial evaluating the drug candidate 177Lu-AKIR001

NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer

The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK

Andelyn and Amplo Biotechnology to manufacture gene therapies for diseases affecting the neuromuscular junction

The partnership reflects a shared commitment to advancing the development and improving access to life-changing therapies

Schrödinger announces discontinuation of SGR-2921 programme

Schrödinger halts clinical development of SGR-2921 CDC7 inhibitor for acute myeloid leukaemia following safety concerns in Phase I study

AMI Pharm advances AYP-101 to Phase III and redefines injectable fat-reduction

AMI Pharm announces that its lead candidate, AYP-101, has entered a pivotal Phase III clinical trial for the treatment of submental fat, commonly referred to as a "double chin"

Novartis announces that both ianalumab Phase III clinical trials met primary endpoints in patients with Sjögren's disease

NEPTUNUS-1 and NEPTUNUS-2 are the first global Phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren's disease

Genmab's EPCORE FL-1 meets dual primary endpoints in Phase III trial for follicular lymphoma

Epcoritamab in combination with rituximab and lenalidomide (R2) demonstrated statistically significant improvement in Overall Response Rate and Progression-Free Survival versus R2 alone in patients with relapsed/refractory follicular lymphoma

Polpharma and Fresenius Kabi sign licensing agreement for proposed biosimilar

Under the terms of the agreement, Polpharma will lead development and manufacturing, whereas Fresenius Kabi will hold exclusive commercialisation rights worldwide, excluding the Middle East and North Africa.

Sponsor content

Meet Navetta: new approach to safety testing of drugs and particles

Turn inhalation research upside down

Sovereign demonstrates turnkey bottle labelling solution at PPMA Total Show 2025

Integrated labelling and tamper-proofing technologies showcased for high-speed production lines

Vapourtec unveils compact benchtop peptide synthesiser

Peptide-Builder uses VBFR technology to improve efficiency and reduce waste

LOCTITE to showcase next generation of healthcare adhesive innovations

New biocompatible adhesives aim to improve safety, performance, and sustainability

Shimadzu’s new UV-1900i Plus – smarter, faster UV-Vis spectrophotometer

Next-generation model offers ultra-fast scans and versatile measurement modes

Suncombe launches compact pH neutralisation systems for labs and small facilities

Expanded SUNpH range delivers compliance and performance in space-limited settings

One family’s journey from diagnosis to gene replacement therapy

How the Krueger family, supported by clinicians, researchers, and manufacturers, accelerated a novel treatment for ultra-rare NEDAMSS in just 14 months

Scalable chemistry and cross-sector expertise at CARBOGEN AMCIS Manchester

How the Manchester site delivers flexible solutions from early-phase synthesis to cosmetics GMP

Inhalytix+ streamlines cascade impaction data analysis

Copley launches connected software to automate inhaler testing workflows

Biotech Fluidics adds peristaltic tubing stop adapter to connector range

New adapter removes need for fixed stoppers and enables custom tubing lengths

New Clara plate combines cell culture and automation in one solution

Porvair Sciences launches 6-well format with integrated filtration options

Anton Paar launches new generation of DMA density meters

New range offers six-digit repeatability, in-house calibration and unmatched measurement precision

Featured companies

CPTx is pioneering in vivo production of precision genetic medicines using single-stranded DNA. Quotient Sciences is a drug development and manufacturing accelerator providing integrated services across the entire development pathway for small-molecule and peptide drug... PCI Pharma Services: Your bridge between life-changing therapies and patients. 3P innovation is a UK-based engineering and custom automation company, delivering innovative solutions to leading major pharmaceutical and medical device companies. We support...
See more